Changes in KPC-producing Klebsiella pneumoniae susceptibility from the pre- to ceftazidime-avibactam era

Infect Dis (Lond). 2022 Apr;54(4):311-313. doi: 10.1080/23744235.2021.2011957. Epub 2021 Dec 6.

Authors

Matteo Boattini^{1

2}, Gabriele Bianco¹, Sara Comini^{1

2}, Marco Iannaccone¹, Roberto Casale^{1

2}, Lorena Charrier², Rossana Cavallo^{1

2}, Cristina Costa^{1

2}

Affiliations

¹ Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, Turin, Italy.
² Department of Public Health and Paediatrics, University of Torino, Turin, Italy.

PMID: 34871146
DOI: 10.1080/23744235.2021.2011957

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Azabicyclo Compounds / therapeutic use
Bacterial Proteins / genetics
Ceftazidime / pharmacology
Ceftazidime / therapeutic use
Drug Combinations
Humans
Klebsiella Infections* / drug therapy
Klebsiella pneumoniae* / genetics
Microbial Sensitivity Tests
beta-Lactamases / genetics

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Bacterial Proteins
Drug Combinations
avibactam, ceftazidime drug combination
Ceftazidime
beta-Lactamases